ODTX Earnings Date: Nov 4, 2026 (Estimated) — Odyssey Therapeutics, Inc.

NASDAQ

Updated Oct 30, 2026

Price $19.72

Market Cap $953.0M

P/E -7.7

52W Range $15.10 – $29.05

Next Earnings Nov 4, 2026 · After close (est.)

When is ODTX's next earnings date?

Odyssey Therapeutics, Inc. (ODTX) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 6:19 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$1.13.

How did ODTX do in its last earnings report?

In its most recent report on Aug 4, 2026 (Q2 2026), Odyssey Therapeutics, Inc. posted EPS of -$1.74 versus the -$0.85 estimate, a miss of 104.7%. Revenue was $0. The stock's 1-day post-earnings move was +10.1%.

How much does ODTX stock move after earnings?

ODTX beat EPS estimates in 0 of its last 2 reported quarters. Over the last 2 reports the stock moved an average of 6.6% (up or down) in the day after earnings.

About Odyssey Therapeutics, Inc.

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.